CompletedNot Applicable

Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

Egypt60 participantsStarted 2024-05-01

Plain-language summary

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18-65 years. * Both sexes. * Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3). * Failure to achieve adequate relief with at least one prophylactic migraine treatment. Exclusion Criteria: * Chronic migraine (≥15 headache days per month). * History of nerve blocks within the last 6 months. * Known allergy to anesthetic agents. * Pregnancy or lactation. * Active psychiatric conditions affecting compliance.

What they're measuring

Degree of headache intensity

Timeframe: 3 months post-procedure

Trial details

NCT IDNCT06997562

SponsorNew Valley University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-03

View on ClinicalTrials.gov More Greater Occipital Nerve Block trials